Drug Costs

Cumplimiento sobre las recomendaciones de uso y evaluación del impacto económico de un programa de uso restringido de imipenem-cilastatina

Chile / Policy making / Humans / Anti-Bacterial Agents / Drug Costs / Imipenem / Costs and Cost Analysis / Imipenem / Costs and Cost Analysis

Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA para el tratamiento antirretroviral inicial

Expert testimony / Clinical Trial / Medical Microbiology / Treatment Outcome / Spain / Decision Trees / Antiretroviral Therapy / Humans / Therapy / Hiv Infection / Cost effectiveness / Efficiency / Health Expenditures / Theoretical Models / Genotype / Adult / Economic Models / Cost Benefit Analysis / Highly Active Antiretroviral Therapy / Drug Costs / Combination drug therapy / Disease Management / Clinical Protocols / Acquired immunodeficiency syndrome / Viral Load / Clinical Trials as Topic / Decision Trees / Antiretroviral Therapy / Humans / Therapy / Hiv Infection / Cost effectiveness / Efficiency / Health Expenditures / Theoretical Models / Genotype / Adult / Economic Models / Cost Benefit Analysis / Highly Active Antiretroviral Therapy / Drug Costs / Combination drug therapy / Disease Management / Clinical Protocols / Acquired immunodeficiency syndrome / Viral Load / Clinical Trials as Topic

Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA para el tratamiento antirretroviral inicial

Expert testimony / Clinical Trial / Medical Microbiology / Treatment Outcome / Spain / Decision Trees / Antiretroviral Therapy / Humans / Therapy / Hiv Infection / Cost effectiveness / Efficiency / Health Expenditures / Theoretical Models / Genotype / Adult / Economic Models / Cost Benefit Analysis / Highly Active Antiretroviral Therapy / Drug Costs / Combination drug therapy / Disease Management / Clinical Protocols / Acquired immunodeficiency syndrome / Viral Load / Clinical Trials as Topic / Decision Trees / Antiretroviral Therapy / Humans / Therapy / Hiv Infection / Cost effectiveness / Efficiency / Health Expenditures / Theoretical Models / Genotype / Adult / Economic Models / Cost Benefit Analysis / Highly Active Antiretroviral Therapy / Drug Costs / Combination drug therapy / Disease Management / Clinical Protocols / Acquired immunodeficiency syndrome / Viral Load / Clinical Trials as Topic

Costes directos sanitarios en pacientes con diabetes mellitus tipo 2 a los seis meses de inicio del tratamiento con insulina en España: estudio INSTIGATE

Treatment Outcome / Comorbidity / Spain / Prospective studies / Humans / Blood Glucose / Insulin / Diabetes mellitus / Europe / Hospitalization / Female / Male / Aged / Middle Aged / Health Expenditures / Oral Hypoglycemic Agents / Drug Costs / Combination drug therapy / Type 2 Diabetes Mellitus / Prospective Study / Blood Glucose / Insulin / Diabetes mellitus / Europe / Hospitalization / Female / Male / Aged / Middle Aged / Health Expenditures / Oral Hypoglycemic Agents / Drug Costs / Combination drug therapy / Type 2 Diabetes Mellitus / Prospective Study

Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA/Plan Nacional sobre el Sida en 2012 para el tratamiento antirretroviral inicial en adultos infectados por el virus de la inmunodeficiencia humana (VIH)

Expert testimony / Clinical Trial / Medical Microbiology / Treatment Outcome / Spain / Decision Trees / Antiretroviral Therapy / Humans / Therapy / Hiv Infection / Cost effectiveness / Efficiency / Health Expenditures / Theoretical Models / Genotype / Adult / Economic Models / Cost Benefit Analysis / Highly Active Antiretroviral Therapy / Drug Costs / Combination drug therapy / Disease Management / Clinical Protocols / Acquired immunodeficiency syndrome / Viral Load / Clinical Trials as Topic / Decision Trees / Antiretroviral Therapy / Humans / Therapy / Hiv Infection / Cost effectiveness / Efficiency / Health Expenditures / Theoretical Models / Genotype / Adult / Economic Models / Cost Benefit Analysis / Highly Active Antiretroviral Therapy / Drug Costs / Combination drug therapy / Disease Management / Clinical Protocols / Acquired immunodeficiency syndrome / Viral Load / Clinical Trials as Topic

Factors influencing global antiretroviral procurement prices

Global Health / Health Policy / Logistic Regression / Humans / United States / Regression Analysis / Income / Least Developed Countries / Socioeconomic Status / Public health systems and services research / Drug Costs / World Health Organization / Universal Access / Linear Regression / Drug Industry / Logistic Regression Model / Linear Regression Model / Regression Analysis / Income / Least Developed Countries / Socioeconomic Status / Public health systems and services research / Drug Costs / World Health Organization / Universal Access / Linear Regression / Drug Industry / Logistic Regression Model / Linear Regression Model

Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA para el tratamiento antirretroviral inicial

Expert testimony / Clinical Trial / Medical Microbiology / Treatment Outcome / Spain / Decision Trees / Antiretroviral Therapy / Humans / Therapy / Hiv Infection / Cost effectiveness / Efficiency / Health Expenditures / Theoretical Models / Genotype / Adult / Economic Models / Cost Benefit Analysis / Highly Active Antiretroviral Therapy / Drug Costs / Combination drug therapy / Disease Management / Clinical Protocols / Acquired immunodeficiency syndrome / Viral Load / Clinical Trials as Topic / Decision Trees / Antiretroviral Therapy / Humans / Therapy / Hiv Infection / Cost effectiveness / Efficiency / Health Expenditures / Theoretical Models / Genotype / Adult / Economic Models / Cost Benefit Analysis / Highly Active Antiretroviral Therapy / Drug Costs / Combination drug therapy / Disease Management / Clinical Protocols / Acquired immunodeficiency syndrome / Viral Load / Clinical Trials as Topic

Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA/Plan Nacional sobre el Sida en 2012 para el tratamiento antirretroviral inicial en adultos infectados por el virus de la inmunodeficiencia humana (VIH)

Expert testimony / Clinical Trial / Medical Microbiology / Treatment Outcome / Spain / Decision Trees / Antiretroviral Therapy / Humans / Therapy / Hiv Infection / Cost effectiveness / Efficiency / Health Expenditures / Theoretical Models / Genotype / Adult / Economic Models / Cost Benefit Analysis / Highly Active Antiretroviral Therapy / Drug Costs / Combination drug therapy / Disease Management / Clinical Protocols / Acquired immunodeficiency syndrome / Viral Load / Clinical Trials as Topic / Decision Trees / Antiretroviral Therapy / Humans / Therapy / Hiv Infection / Cost effectiveness / Efficiency / Health Expenditures / Theoretical Models / Genotype / Adult / Economic Models / Cost Benefit Analysis / Highly Active Antiretroviral Therapy / Drug Costs / Combination drug therapy / Disease Management / Clinical Protocols / Acquired immunodeficiency syndrome / Viral Load / Clinical Trials as Topic

Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA/Plan Nacional sobre el Sida en 2013 para el tratamiento antirretroviral inicial en adultos infectados por el virus de la inmunodeficiencia humana

Expert testimony / Clinical Trial / Medical Microbiology / Treatment Outcome / Spain / Decision Trees / Antiretroviral Therapy / Humans / Therapy / Hiv Infection / Cost effectiveness / Efficiency / Health Expenditures / Theoretical Models / Genotype / Adult / Economic Models / Cost Benefit Analysis / Highly Active Antiretroviral Therapy / Drug Costs / Combination drug therapy / Disease Management / Clinical Protocols / Acquired immunodeficiency syndrome / Viral Load / Clinical Trials as Topic / Decision Trees / Antiretroviral Therapy / Humans / Therapy / Hiv Infection / Cost effectiveness / Efficiency / Health Expenditures / Theoretical Models / Genotype / Adult / Economic Models / Cost Benefit Analysis / Highly Active Antiretroviral Therapy / Drug Costs / Combination drug therapy / Disease Management / Clinical Protocols / Acquired immunodeficiency syndrome / Viral Load / Clinical Trials as Topic

Do Higher-Priced Generic Medicines Enjoy a Competitive Advantage Under Reference Pricing?

Marketing / Applied Economics / Spain / Humans / Generic Drugs / Economic Competition / Public health systems and services research / Drug Costs / Pharmacies / Economic Competition / Public health systems and services research / Drug Costs / Pharmacies

Do Higher-Priced Generic Medicines Enjoy a Competitive Advantage Under Reference Pricing?

Marketing / Applied Economics / Spain / Humans / Generic Drugs / Economic Competition / Public health systems and services research / Drug Costs / Pharmacies / Economic Competition / Public health systems and services research / Drug Costs / Pharmacies

La prescripción farmacéutica en atención primaria. Informe SESPAS 2012

Primary Care / Primary Health Care / Public Health / Quality Control / Spain / Pharmaceutical industry / Humans / Cost effectiveness / National Health Service / Case Management / Government Agencies / Self medication / Patient Care / Cost Benefit Analysis / Drug Costs / Polypharmacy / Low Risk / Health Priorities / Drug Utilization / Electronic Medical Record / Pharmaceutical industry / Humans / Cost effectiveness / National Health Service / Case Management / Government Agencies / Self medication / Patient Care / Cost Benefit Analysis / Drug Costs / Polypharmacy / Low Risk / Health Priorities / Drug Utilization / Electronic Medical Record

[Pharmaceutical prescription in primary care. SESPAS report 2012]

Primary Care / Primary Health Care / Public Health / Quality Control / Spain / Pharmaceutical industry / Humans / Cost effectiveness / National Health Service / Case Management / Government Agencies / Self medication / Patient Care / Cost Benefit Analysis / Drug Costs / Polypharmacy / Low Risk / Health Priorities / Drug Utilization / Electronic Medical Record / Pharmaceutical industry / Humans / Cost effectiveness / National Health Service / Case Management / Government Agencies / Self medication / Patient Care / Cost Benefit Analysis / Drug Costs / Polypharmacy / Low Risk / Health Priorities / Drug Utilization / Electronic Medical Record

Dabigatrón versus acenocumarol para la prevención del ictus en la fibrilación atrial: análisis de impacto presupuestario en un departamento sanitario

Spain / Stroke / Humans / Female / Atrial Fibrillation / Anticoagulants / Aged / Middle Aged / Budgets / Public health systems and services research / Cost Benefit Analysis / Drug Costs / Benzimidazoles / Anticoagulants / Aged / Middle Aged / Budgets / Public health systems and services research / Cost Benefit Analysis / Drug Costs / Benzimidazoles

Physicians’ preferences for prescribing oral and intravenous anticancer drugs: A Discrete Choice Experiment

Medication Adherence / Conjoint Analysis / France / Medical Decision Making / Humans / Female / Male / Regression Analysis / Aged / Middle Aged / Questionnaires / Adult / Neoplasms / Drug Costs / Logistic Regression Model / Antineoplastic Agents / Quantitative Method / Anticancer Drug / Female / Male / Regression Analysis / Aged / Middle Aged / Questionnaires / Adult / Neoplasms / Drug Costs / Logistic Regression Model / Antineoplastic Agents / Quantitative Method / Anticancer Drug

Physicians’ preferences for prescribing oral and intravenous anticancer drugs: A Discrete Choice Experiment

Medication Adherence / Conjoint Analysis / France / Medical Decision Making / Humans / Female / Male / Regression Analysis / Aged / Middle Aged / Questionnaires / Adult / Neoplasms / Drug Costs / Logistic Regression Model / Antineoplastic Agents / Quantitative Method / Anticancer Drug / Female / Male / Regression Analysis / Aged / Middle Aged / Questionnaires / Adult / Neoplasms / Drug Costs / Logistic Regression Model / Antineoplastic Agents / Quantitative Method / Anticancer Drug
Copyright © 2017 DATOSPDF Inc.